Intellia Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Intellia Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2015 to 2023.
  • Intellia Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$145M, a 10.4% decline year-over-year.
  • Intellia Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$538M, a 10.8% decline year-over-year.
  • Intellia Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$515M, a 12.5% decline from 2022.
  • Intellia Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$458M, a 71.1% decline from 2021.
  • Intellia Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$268M, a 96.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$515M -$57.1M -12.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$458M -$190M -71.1% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$268M -$131M -96.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$137M -$30.2M -28.4% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$106M -$15.5M -17.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 -$90.9M -$21.3M -30.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$69.6M -$37.4M -116% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$32.2M -$18.8M -140% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$13.4M Jan 1, 2015 Dec 31, 2015 10-K 2018-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.